Cytocine™ Cryopreserved Primary Porcine Hepatocytes offer a valuable alternative to human hepatocytes for preclinical research applications. With high viability, plateability, metabolic functionality, and scalability, Cytocine™ hepatocytes provide a reliable and cost-effective solution for researchers who need a consistent supply of cells for their experiments. Dive into our latest White Paper to learn more about this new source of high-quality liver cells to support biomedical research.

ROCHESTER, Minnesota, Oct. 11, 2024 – Cytotheryx, Inc., a privately held company focused on the development of a consistent, high-quality source of human hepatocytes (liver

We are thrilled to share that the Rochester City Council has approved sponsoring Cytotheryx for applications to the Minnesota Department of Employment and Economic Development for the Minnesota Investment Fund and the Minnesota Job Creation Fund. We are hoping to secure a total of $870,000 in funding to support expansion in Rochester to further our mission.

We are excited to share that Cytotheryx participated in the prestigious MN Ventures Startup Showcase. Launch Minnesota, in collaboration with the University of Minnesota, Medical Alley, and MNSBIR, Inc., hosted this exclusive gathering to spotlight innovative local startups and connect them with investors from across the country.

We are thrilled to announce that Ponte Biosciences, a subsidiary of Cytotheryx, emerged as the grand prize winner at the inaugural Avio Medtech Consulting pitch competition during the 23rd Annual Medtech MVP event in Minneapolis. This recognition comes with a $20,000 non-dilutive funding award, a boost for our work in developing life-saving technology for patients with acute liver failure.

Cytotheryx, Inc. announced today it has acquired the intellectual property assets of Ambys Medicines, Inc., which will now become part of our portfolio.

We’re honored to have received a grant from Launch Minnesota Innovation Grants, which honors promising innovative, scalable technology businesses in the state.

Rochester Area Economic Development Inc. (RAEDI) has honored Cytotheryx with a Recognizing Award Valuing Entrepreneurs (R.A.V.E.) award.

Regenerative Medicine Minnesota (RMM) has awarded Cytotheryx with the prestigious biobusiness development grant, which will enable our continued focused innovation.

The Medical Alley Association interviewed Cytotheryx CEO Dr. John Swart to discuss Cytotheryx’ innovative work. Find the whole conversation here.

We’re proud to be part of the cell and gene therapy community, and to participate in conferences like Meeting on the Mesa where we can build partnerships.

Cytotheryx is excited to share we’ve been selected as a finalist for the 10th Annual BOLD Awards, which honor innovative and inspirational organizations.

The Cytotheryx team is committed to community volunteering. We’re proud to have spent time volunteering together to keep our city clean and beautiful.

The Cytotheryx team is humbled and honored to have been selected as a 2022 Early Stage BOLD Award Winner at the 10th Annual BOLD Awards!

Cytotheryx received a full AAALAC International accreditation, the highest certification level. Learn what this accreditation means and how we achieved it.